Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

29.63 +0.30 (+1.02%)
Streaming Delayed Price Updated: 1:18 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Harmony Biosciences Holdings (NASDAQ:HRMY) Beats Q3 2025 Estimates Despite Muted Market Reaction
Harmony Biosciences Q3 2025 earnings beat estimates with strong WAKIX growth. Despite the beat, stock dipped slightly in pre-market trading. 
Via Chartmill
Topics Earnings
Earnings Scheduled For November 4, 2025
 
Via Benzinga
Earnings Preview For Harmony Biosciences
 
Via Benzinga
Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime GARP Investment with Strong Growth and a Reasonable Price
Harmony Biosciences (HRMY) offers strong growth at a reasonable price. With high EPS growth, robust profitability, and a low P/E ratio, it's a top GARP stock. 
Via Chartmill
Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?
Via Stocktwits
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Undervalued Investment Case
Harmony Biosciences (HRMY) is a value stock with a low P/E ratio, strong profitability, a healthy balance sheet, and solid growth potential. 
Via Chartmill
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Q3 2025 Earnings Season: A Market Navigating AI's Ascent Amidst Economic Shifts
The curtain has largely fallen on the Q3 2025 earnings season, revealing a financial landscape characterized by robust corporate performance, particularly in the technology and financial sectors,... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
Harmony Biosciences Holdings (NASDAQ:HRMY): A Growth Stock with a Promising Technical Setup
Harmony Biosciences (HRMY) offers strong growth, high profitability, and an attractive valuation. Its positive technical setup suggests a potential breakout, making it a compelling stock to watch. 
Via Chartmill
Top 3 Health Care Stocks That Are Preparing To Pump In Q4
 
Via Benzinga
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents an 'Affordable Growth' Opportunity
Harmony Biosciences (HRMY) offers affordable growth with strong EPS & revenue expansion, a low P/E ratio, and robust profitability in rare neurological treatments. 
Via Chartmill
Deep Dive Into Harmony Biosciences Hldgs Stock: Analyst Perspectives (6 Ratings)
Analysts' ratings for Harmony Biosciences Hldgs (NASDAQ: HRMY) over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below... 
Via Benzinga
Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday
 
Via Benzinga
Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study
The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate. 
Via Stocktwits
Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study
Harmony Biosciences' ZYN002 failed to meet its primary goal in a Fragile X Phase 3 trial, but the company points to pipeline growth. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Harmony Biosciences Whiffs In 'Undruggable' Genetic Disease; Shares Tumble
Shares plunged Wednesday as the inherited disease continued to be "undruggable" for the biotech company. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity
Harmony Biosciences (HRMY) is a value stock with strong fundamentals: low P/E, high profitability, robust financial health, and impressive growth prospects. 
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Top Affordable Growth Stock
Harmony Biosciences (HRMY) exemplifies GARP investing with strong EPS growth, a low P/E ratio, and robust profitability in the rare neurology sector. 
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity
Harmony Biosciences (HRMY) is a value stock with strong fundamentals: undervalued P/E, high profitability, robust financial health, and impressive growth metrics. 
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime Affordable Growth Stock with Strong Fundamentals
Harmony Biosciences (HRMY) offers strong growth, solid valuation, and financial health, making it an ideal pick for Affordable Growth investors seeking high potential at reasonable prices. 
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY): A Strong Growth Stock with Promising Technical Setup
Harmony Biosciences (HRMY) offers strong growth potential with solid fundamentals, high profitability, and a bullish technical setup, making it an attractive stock for investors. 
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity with Strong Fundamentals and Growth Potential
Harmony Biosciences (HRMY) is undervalued with strong fundamentals—low P/E, high profitability, solid financials, and robust growth, making it a prime value investing opportunity. 
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Growth Stock with Attractive Valuation
Harmony Biosciences (HRMY) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the pharmaceutical... 
Via Chartmill
6 Analysts Assess Harmony Biosciences Hldgs: What You Need To Know
 
Via Benzinga
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) – An Undervalued Stock with Strong Fundamentals
HARMONY BIOSCIENCES (HRMY) is an undervalued pharmaceutical stock with strong profitability, financial health, and growth potential, making it a candidate for value investors. 
Via Chartmill
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) - A Strong Candidate for Affordable Growth Investors
HARMONY BIOSCIENCES (HRMY) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the pharmaceutical... 
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Potentially Undervalued Stock in the Pharmaceutical Sector
Harmony Biosciences (HRMY) presents a compelling value opportunity with strong profitability, financial health, and growth—all at an attractive valuation. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.